Comparative Pharmacology
Head-to-head clinical analysis: DORIDEN versus SONATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIDEN versus SONATA.
DORIDEN vs SONATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate-like sedative-hypnotic; acts on GABA-A receptors to enhance inhibitory neurotransmission, causing CNS depression.
Zaleplon is a non-benzodiazepine hypnotic that selectively binds to the benzodiazepine type 1 (BZ1) receptor subtype on the gamma-aminobutyric acid (GABA) A receptor complex, potentiating GABA-mediated chloride ion influx and neuronal inhibition.
500 mg orally at bedtime, maximum 1 g per day; for sedation, 250 mg 3 times daily after meals.
10 mg orally at bedtime; range 5-20 mg; maximum 20 mg per day.
None Documented
None Documented
Terminal elimination half-life is 4-10 hours in healthy adults; prolonged in elderly and patients with hepatic impairment, increasing to 12-20 hours.
Terminal elimination half-life is approximately 1 hour (range 0.7–1.7 h) in healthy adults; elderly patients and those with hepatic impairment may have prolonged half-life (up to 2–3 h).
Renal (accounting for approximately 80% of elimination, primarily as glucuronide conjugates and unchanged drug); biliary/fecal (minor, about 10%).
Approximately 83% of administered radioactivity is excreted in urine (with less than 1% as unchanged drug) and 17% in feces.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic